Yintoni iMounjaro(Tirzepatide)?

I-Mounjaro(Tirzepatide) lichiza lokunciphisa umzimba kunye nokugcinwa okuqulethe into esebenzayo i-tirzepatide. I-Tirzepatide yi-GIP esebenza ixesha elide kunye ne-GLP-1 ye-receptor agonist. Zombini ii-receptors zifumaneka kwi-pancreatic alpha kunye neeseli ze-beta ze-endocrine, intliziyo, imithwalo yegazi, iiseli ze-immune (leukocytes), amathumbu kunye nezintso. Ii-receptors ze-GIP nazo zifumaneka kwi-adipocytes.
Ukongeza, zombini ii-receptors ze-GIP kunye ne-GLP-1 zibonakaliswa kwimimandla yobuchopho ebalulekileyo kulawulo lokutya. I-Tirzepatide ikhetha kakhulu i-GIP yabantu kunye ne-GLP-1 receptors. I-Tirzepatide inobudlelwane obuphezulu kuzo zombini i-GIP kunye ne-GLP-1 receptors. Umsebenzi we-tirzepatide kwii-receptors ze-GIP ufana ne-hormone ye-GIP yendalo. Umsebenzi we-tirzepatide kwii-receptors ze-GLP-1 ungaphantsi kunalowo we-hormone yendalo ye-GLP-1.
I-Mounjaro (i-Tirzepatide) isebenza ngokusebenza kwi-receptors engqondweni elawula ukutya, ikwenza uzive uhluthi, ulambile, kwaye unqabile ukuba unqwenele ukutya. Oku kuya kukunceda ukuba utye kancinci kwaye unciphise umzimba.
I-Mounjaro kufuneka isetyenziswe ngesicwangciso sokutya esincitshisiweyo sekhalori kunye nokwandisa umsebenzi womzimba.

Iikhrayitheriya zokuBandakanya

I-Mounjaro (i-Tirzepatide) iboniswa kulawulo lobunzima, kubandakanywa ukulahleka kwesisindo kunye nokugcinwa, njengenxalenye yokutya okuncitshisiweyo kwekhalori kunye nokwandisa umsebenzi womzimba kubantu abadala abane-first body mass index (BMI) ye:
≥ 30 kg / m2 (otyebileyo), okanye
≥ 27 kg / m2 ukuya <30 kg / m2 (ubunzima obukhulu) ubuncinane obunye ubunzima obunxulumene nobunzima obufana ne-dysglycemia (i-prediabetes okanye uhlobo lwe-2 yeswekile), i-hypertension, i-dyslipidemia, okanye i-apnea ephazamisayo yokulala Imvume yonyango kunye nokuthotyelwa kokutya okwaneleyo kokutya.
Ubudala 18-75 iminyaka
Ukuba isigulane asiphumeleli ukulahlekelwa ubuncinane i-5% yobunzima bomzimba wokuqala emva kweenyanga ze-6 zonyango, isigqibo kufuneka senziwe ukuba siqhubeke nonyango, kuthathelwa ingqalelo inzuzo / ingozi yeprofayili yesigulane ngasinye.

Ishedyuli yokuchitha

I-dose yokuqala ye-tirzepatide yi-2.5 mg kanye ngeveki. Emva kweeveki ze-4, umthamo kufuneka unyuswe kwi-5 mg kanye ngeveki. Ukuba kuyimfuneko, idosi inokunyuswa nge-2.5 mg ubuncinane kwiiveki ze-4 phezu kwedosi yangoku.
Iidosi zokulondolozwa ezicetyiswayo ziyi-5, i-10, kunye ne-15 mg.
Ubuninzi bedosi yi-15 mg kanye ngeveki.

Indlela yokuthatha

IMounjaro(Tirzepatide) inokulawulwa kanye ngeveki nangaliphi na ixesha lemini, kunye okanye ngaphandle kokutya.
Kufuneka itofwe ngaphantsi kwesikhumba, ethangeni, okanye engalweni. Indawo yokutofa inokutshintshwa. Akufanele ifakwe nge-intramuscularly okanye nge-intramuscularly.
Ukuba kuyimfuneko, usuku lwedosi lweveki lunokutshintshwa nje ixesha eliphakathi kweedosi ubuncinane iintsuku ezi-3 (> iiyure ezingama-72). Nje ukuba usuku olutsha lwedosi lukhethiwe, ithamo kufuneka liqhubeke kanye ngeveki.
Izigulane kufuneka zicetyiswe ukuba zifunde imiyalelo yokusetyenziswa kwipakethi efakwe ngononophelo phambi kokuthatha iyeza.